<?xml version='1.0' encoding='UTF-8'?>
<extracted-tables-set><pmcid>6372554</pmcid><all-ids><article-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" pub-id-type="pmid">30787862</article-id><article-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" pub-id-type="pmc">6372554</article-id><article-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" pub-id-type="doi">10.3389/fnins.2019.00040</article-id></all-ids><extracted-table><table-id>T1</table-id><table-label>Table 1</table-label><table-caption>Demographic and clinical characteristics of participants.</table-caption><original-table><table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="T1" position="float"><label>Table 1</label><caption><p>Demographic and clinical characteristics of participants.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"><bold>Characteristics</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>SCZ patients (<italic>n</italic> = 20)</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>Healthy controls(<italic>n</italic> = 26)</bold></th><th valign="top" align="center" colspan="2" style="border-bottom: thin solid #000000;" rowspan="1"><bold>Group comparison</bold></th></tr><tr><th rowspan="1" colspan="1"/><th valign="top" align="center" rowspan="1" colspan="1"><bold>Mean (SD)</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>Mean (SD)</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold><italic>t</italic> or <italic><bold>χ</bold><sup>2</sup></italic></bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold><italic>p</italic></bold></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Age (years)</td><td valign="top" align="center" rowspan="1" colspan="1">29.1 (8.0)</td><td valign="top" align="center" rowspan="1" colspan="1">26.0 (4.5)</td><td valign="top" align="center" rowspan="1" colspan="1">−1.606</td><td valign="top" align="left" rowspan="1" colspan="1">0.115</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Gender: M/F</td><td valign="top" align="center" rowspan="1" colspan="1">7/13</td><td valign="top" align="center" rowspan="1" colspan="1">6/7</td><td valign="top" align="center" rowspan="1" colspan="1">0.580</td><td valign="top" align="left" rowspan="1" colspan="1">0.446</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Education (years)</td><td valign="top" align="center" rowspan="1" colspan="1">13.9 (3.9)</td><td valign="top" align="center" rowspan="1" colspan="1">14.5 (2.2)</td><td valign="top" align="center" rowspan="1" colspan="1">0.604</td><td valign="top" align="left" rowspan="1" colspan="1">0.549</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Duration of illness (months)</td><td valign="top" align="center" rowspan="1" colspan="1">30.02 (25.17)</td><td valign="top" align="center" rowspan="1" colspan="1">\</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Episode</td><td valign="top" align="center" rowspan="1" colspan="1">1.2 (0.6)</td><td valign="top" align="center" rowspan="1" colspan="1">\</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">PANSS-total</td><td valign="top" align="center" rowspan="1" colspan="1">81.7 (12.0)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Positive symptoms</td><td valign="top" align="center" rowspan="1" colspan="1">22.4 (5.8)</td><td valign="top" align="center" rowspan="1" colspan="1">\</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Negative symptoms</td><td valign="top" align="center" rowspan="1" colspan="1">20.2 (5.9)</td><td valign="top" align="center" rowspan="1" colspan="1">\</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">General symptoms</td><td valign="top" align="center" rowspan="1" colspan="1">39.2 (5.3)</td><td valign="top" align="center" rowspan="1" colspan="1">\</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CGI</td><td valign="top" align="center" rowspan="1" colspan="1">5 (0.88)</td><td valign="top" align="center" rowspan="1" colspan="1">\</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Medication (CPZ eq mg/day)</td><td valign="top" align="center" rowspan="1" colspan="1">516.05 (157.45)</td><td valign="top" align="center" rowspan="1" colspan="1">\</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><p><italic>SCZ, schizophrenia; PANSS, positive and negative syndrome scale, which includes positive symptoms, negative symptoms and general psychopathology subscales; CGI, clinical global impression; CPZ eq, chlorpromazine equivalence; SD, standard deviation</italic>.</p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 1<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Demographic and clinical characteristics of participants.</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left">Characteristics</th><th valign="top" align="center">SCZ patients (n = 20)</th><th valign="top" align="center">Healthy controls(n = 26)</th><th valign="top" align="center" colspan="2" style="border-bottom: thin solid #000000;">Group comparison</th></tr><tr><th/><th valign="top" align="center">Mean (SD)</th><th valign="top" align="center">Mean (SD)</th><th valign="top" align="center">t or χ2</th><th valign="top" align="left">p</th></tr></thead><tbody><tr><td valign="top" align="left">Age (years)</td><td valign="top" align="center">29.1 (8.0)</td><td valign="top" align="center">26.0 (4.5)</td><td valign="top" align="center">−1.606</td><td valign="top" align="left">0.115</td></tr><tr><td valign="top" align="left">Gender: M/F</td><td valign="top" align="center">7/13</td><td valign="top" align="center">6/7</td><td valign="top" align="center">0.580</td><td valign="top" align="left">0.446</td></tr><tr><td valign="top" align="left">Education (years)</td><td valign="top" align="center">13.9 (3.9)</td><td valign="top" align="center">14.5 (2.2)</td><td valign="top" align="center">0.604</td><td valign="top" align="left">0.549</td></tr><tr><td valign="top" align="left">Duration of illness (months)</td><td valign="top" align="center">30.02 (25.17)</td><td valign="top" align="center">\</td><td/><td/></tr><tr><td valign="top" align="left">Episode</td><td valign="top" align="center">1.2 (0.6)</td><td valign="top" align="center">\</td><td/><td/></tr><tr><td valign="top" align="left">PANSS-total</td><td valign="top" align="center">81.7 (12.0)</td><td/><td/><td/></tr><tr><td valign="top" align="left">Positive symptoms</td><td valign="top" align="center">22.4 (5.8)</td><td valign="top" align="center">\</td><td/><td/></tr><tr><td valign="top" align="left">Negative symptoms</td><td valign="top" align="center">20.2 (5.9)</td><td valign="top" align="center">\</td><td/><td/></tr><tr><td valign="top" align="left">General symptoms</td><td valign="top" align="center">39.2 (5.3)</td><td valign="top" align="center">\</td><td/><td/></tr><tr><td valign="top" align="left">CGI</td><td valign="top" align="center">5 (0.88)</td><td valign="top" align="center">\</td><td/><td/></tr><tr><td valign="top" align="left">Medication (CPZ eq mg/day)</td><td valign="top" align="center">516.05 (157.45)</td><td valign="top" align="center">\</td><td/><td/></tr></tbody></table></div>SCZ, schizophrenia; PANSS, positive and negative syndrome scale, which includes positive symptoms, negative symptoms and general psychopathology subscales; CGI, clinical global impression; CPZ eq, chlorpromazine equivalence; SD, standard deviation.</transformed-table></extracted-table></extracted-tables-set>